Zhongguancun (000931.SZ) subsidiary's application for marketing authorization of Duotinore tablets has been accepted.

According to the Zhitong Finance APP, Zhongguancun (000931.SZ) announced that its subsidiary Beijing Huasu Pharmaceutical Co., Ltd. recently received an "Acceptance Notification" issued by the National Medical Products Administration, indicating that the application for marketing authorization of Dutrebanor Tablets (specifications: 1mg, 2mg) has been accepted. Dutrebanor Tablets are indicated for patients with gout accompanied by hyperuricemia and can selectively inhibit the urate reabsorption transporter URAT1 in the kidneys, promoting the excretion of uric acid through urine by glomerular filtration and reducing blood uric acid levels.